This project is supported by an educational grant from AstraZeneca.
There are numerous challenges for clinicians who manage patients with hepatocellular cancer (HCC). This includes diagnosing and staging patients in a timely manner while staying abreast with the latest clinical advances in the field. The Association of Community Cancer Centers (ACCC)—in partnership with the American Society for Clinical Pathology (ASCP), the Society of Interventional Oncology (SIO) and the France Foundation (TFF), —is committed to ensuring providers are equipped with the knowledge needed to develop practical protocols to inform personalized treatment options for HCC patients.
The goal of this initiative is to provide the latest clinical information to increase clinicians’ knowledge and improve their competence confidence in providing the most accurate recommendations for treatment as members of the multidisciplinary HCC cancer treatment team.
Content includes the clinical profiles of current and emerging immunotherapy agents as well as the use of these agents in combination, in succession, and sequentially with interventional arterially directed therapy (ADT).
Participants will actively engage in interactive small-group activities, including:
Upon completion of the activity, participants should be able to:
This activity is jointly provided by The France Foundation, Society of Interventional Oncology, American Society for Clinical Pathology, and Association of Community Cancer Centers.
This activity will award AMA PRA Category 1 Credit(s)™ and nursing contact hours.
For additional CE information, please visit tffevents.com/hcc.